Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
79 hedge funds and large institutions have $128M invested in Harpoon Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 19 closing their positions.
4% more call options, than puts
Call options by funds: $193K | Put options by funds: $185K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 84 → 79 (-5)
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
35% less capital invested
Capital invested by funds: $196M → $128M (-$68.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.69M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.58M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$2.34M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.35M |
| 5 |
Renaissance Technologies
New York
|
+$827K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$14.6M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.59M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.78M |
| 4 |
Two Sigma Investments
New York
|
-$887K |
| 5 |
Two Sigma Advisers
New York
|
-$677K |
HARP Hedge Fund Activity: Q1 2022 in Review
79 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q1 2022, worth a combined $128M — down 35% from $196M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of HARP and 14 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 21 added.
The largest buyer was Point72 Asset Management, adding an estimated $2.69M. The largest seller was Logos Global Management, exiting entirely with an estimated $14.6M sold.
- 79 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q1 2022, down from 84 in Q4 2021.
- Funds reported $128M of Harpoon Therapeutics, Inc. Common Stock stock for Q1 2022, down 35% quarter-over-quarter.
- 14 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q1 2022 and 19 closed out, a net change of -5 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q1 2022 was Point72 Asset Management, an estimated $2.69M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q1 2022 was Logos Global Management, an estimated $14.6M sold.
Based on aggregated 13F filings for Q1 2022.